Intellia Q1 net loss $107M; cash $953M; Phase 3 enrollment ahead; FDA alignment on ATTRv-PN trial

Intellia Therapeutics, Inc.

2024-Q1 EPS reported -$1.12 revenue$28,935,000

Net loss of $107.4M for Q1 2024; collaboration revenue $28.9M (up from $12.6M YoY) on $21M non-cash adjustment.
Cash and marketable securities $953.4M as of Mar 31, 2024; expected to fund operations into late 2026.
Phase 3 MAGNITUDE trial for ATTR-CM enrolling ahead of projections; over 30 patients dosed, 40+ in screening.
FDA alignment on pivotal Phase 3 design for NTLA-2001 in ATTRv-PN; study of ~50 patients to initiate by year-end.
On track to initiate NTLA-2002 Phase 3 for HAE in H2 2024; Phase 1 long-term data at EAACI June 2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Intellia Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2024.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.